02315 BIOCYTOGEN-B
- 8.950
- -0.310-3.35%
BIOCYTOGEN-B News
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Biocytogen Pharmaceuticals' Loss Narrows in 2023
Biocytogen Pharmaceuticals (Beijing) (HKG:2315) cut its losses to roughly 383 million yuan in 2023 from nearly 602.2 million yuan in the preceding year, according to a Thursday filing with the Hong Ko
百奧賽圖-B：2023年度報告
Featured announcements | Shandong Gold's Q1 net profit is expected to increase by 48.11% to 70.9% year-on-year
Xinji Shaxi: 14.16% of the company's shares held by the controlling shareholder were forcibly sold, and trading resumed today; express sales: net profit of 195.9 billion yen in the first half of the year, up 27.7% year on year; Smore International: profit after tax for the first quarter was about 339.5 million yuan, up 12.8% year on year.
Biosetu-B (02315.HK) is expected to approach the break-even point in 2024 and plans to make further share purchases of no more than HK$10 million
Gelonghui announced on April 11 | Biosetu-B (02315.HK) announced that the company noticed unusual fluctuations in the stock price of the company's shares listed on the Hong Kong Stock Exchange Limited recently. The company hereby explains that there have been no major adverse events in its production and operation activities, and that all business lines have maintained steady growth and are progressing steadily in accordance with the established strategy. The company's board of directors and management team are confident in the company's development prospects and do not expect any significant adverse changes in the company's production and operation activities and financial situation. As disclosed in the overseas regulatory announcement on January 5, 2024, according to the company's careful calculations, the company is expected to reach 20
Baiaosetu (2315.HK) 2023 review: Overseas revenue is growing rapidly, Qianmu Wanbang has completed phased R&D, and the self-research pipeline is successfully authorized and transferred to the outside world
Incident The company announced 2023 results: in 2023, revenue of 717 million yuan (+34%), overseas revenue of 408 million yuan (+66%), gross margin of 70.6% (+2.8pp), net profit loss
Baiosaitu-B (02315.HK) announced annual results: revenue reached 717 million yuan, up more than 34% year on year, and overseas market orders and revenue grew strongly
Baiosetu-B (02315.HK) announced its annual results. For the year ended December 31, 2023, the Group achieved operating income of approximately RMB 717 million, an increase of 34.3%; gross profit of approximately RMB 506 million, up 29.2% year on year, and gross profit margin of 70.6%, maintaining a high level. Annual losses narrowed sharply by about 36.4%% to RMB 383 million. During the reporting period, the results of continuing to expand overseas markets were remarkable, and overseas sales revenue continued to grow rapidly. Overseas market revenue surged 65.9% year over year to RMB 408 million, accounting for a share of total revenue
Understand Baiosetu-B (02315.HK)'s 2023 annual results in one picture
On the evening of March 26, Biosetu-B (02315.HK) announced the results for the year ended December 31, 2023. In 2023, the Group achieved revenue of RMB 717 million (same unit), an increase of 34% over the previous year. Among them, overseas revenue reached 408 million yuan, an increase of 66% over the previous year, and a gross profit margin of 71%, which is basically stable at a high level. Here's a picture to understand Baiosetu-B (02315.HK)'s 2023 results.
Baiosaitu-B (02315.HK): Achieved revenue of 717 million yuan in 2023, an increase of 34.3% year-on-year
On March 27, GLONGHUI | Biosetu-B (02315.HK) announced that for the year ended December 31, 2023, revenue increased by 34.3% year-on-year to approximately RMB 717 million. The increase was mainly due to increased revenue from model animal sales and antibody development. Gross profit (that is, revenue reduced sales costs) increased 29.2% year over year to approximately RMB 506 million. The increase in gross profit was mainly due to increased revenue from model animal sales and antibody development. The company's business model corresponds to the transfer of early antibody sequences produced by “thousands of antibodies” and joint development/authorized transfer/transfer development
BIOCYTOGEN-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Baiosetu and ABL Bio have reached a cooperation to jointly develop a novel dual-antibody ADC drug
BEIJING, March 25, 2024/PRNewswire/ -- Baiaosetu (Beijing) Pharmaceutical Technology Co., Ltd. (“BEIJING”, stock code 02315.HK), an international biotechnology company with innovative technology that drives the development of new antibody-like drugs, today announced a partnership with ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean biotech company that develops novel therapeutics for tumors and central nervous system diseases in the clinical phase to jointly develop novel bispecific antibody-conjugated drugs (dual-antibody ADC). RenLiT
Baiosetu-B (02315.HK) plans to hold a board meeting on March 27 to consider and approve the annual results
Glonghui, March 15, 丨 Baiosetu-B (02315.HK) announced that the board of directors meeting will be held on March 27, 2024 (Wednesday) to (i) consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and (ii) consider the payment of a final dividend (if any).
BIOCYTOGEN-B: DATE OF BOARD MEETING
Baiosaitu-B (02315.HK) expects annual revenue of 713 million yuan to 723 million yuan, a year-on-year increase of about 33.5%-35.4%
Gelonghui, Feb. 23 | Baiosetu-B (02315.HK) announced that for the year ended December 31, 2023, the Group's revenue for 2023 is estimated to be approximately RMB 712.9 million to RMB 722.9 million. Compared with the financial statement data for the same period last year, it will increase by about RMB 179.0 million to RMB 189.0 million, an increase of about 33.5% to 35.4% over the previous year. The Group's annual loss for 2023 is estimated to be approximately RMB 377.1 million to RMB 387.1 million. Compared with the financial statement data for the same period last year, this will decrease
Selected announcements | Air China's passenger turnover increased by nearly 70% year-on-year in January; Xinhua Insurance's premium income fell by more than 15% in January
China Eastern Airlines shares: passenger turnover increased 87.97% year on year in January; China Southern Airlines shares: passenger turnover increased 56.47% year on year in January; Kuaishou-W: spent HK$39.97 million to buy back 912,000 shares on February 19.
Baiosetu-B (02315.HK) and Gilead reach multi-target antibody cooperation agreement
On February 19, GLONGHUI announced that it has reached an antibody evaluation and selection agreement with Gilead Sciences. The agreement authorized Gilead to conduct antibody evaluations for relevant targets using a whole-human antibody library established by Biosetu against a broad range of drug targets. During the three-year nomination period, Gilead will nominate multiple targets of interest to them and evaluate corresponding antibodies, and have the right to select specific antibodies for use in the development of therapeutic products worldwide. Under the agreement, Bioosetu will receive a payment to enable Gilead to evaluate specific antibodies against selected targets. Selected for each nominated target
Selected Announcements | China's annual net profit increased 33% year over year; JD: Its subsidiary Dada announced that questionable behavior was discovered during internal audits
Yuexiu Real Estate's cumulative contract sales amount in 2023 was about 142.03 billion yuan, up 13.6% year on year; CGN Power: total feed-in electricity volume in 2023 was 214.146 billion kilowatt-hours, up 7.95% year on year; Sansheng Pharmaceutical: Mandy Foam was approved for listing.
Biocytogen Pharmaceuticals Gets License for Radiance Biopharma's Tumor Drug
Biocytogen Pharmaceuticals (Beijing) (HKG:2315) received an exclusive license to manufacture and market Radiance Biopharma's fully human anti-HER2 and TROP2 bispecific antibody drug conjugate, BsADC,
Baiosaitu (02315.HK): The core business is stable, the innovative business is poised to accelerate, and profits can be expected in 24 years
Recently, Baiosetu (02315.HK), which has already been listed on the Hong Kong Stock Exchange, submitted a response to the review inquiry letter on the Science and Technology Innovation Board listing application documents to the Shanghai Stock Exchange and has updated and submitted relevant financial information to continue the IPO process on the Science and Technology Innovation Board. With the previous special label of “the first gene-edited stock” of Hong Kong stocks, and it is also one of the few biotechnology companies in the Hong Kong stock market that has both revenue support and actively invests in cutting-edge innovation fields, Baiosetu has a high level of recognition in the capital market, and I believe that the market's attention will remain online. The author noticed that the company is currently also entering a new stage of development
Bioosetu and Lepuchuang collaborated to develop multi-specific T-cell connector drugs based on WT1 TCR antibodies and achieved milestone progress
BEIJING and SHANGHAI, December 27, 2023 /PRNewswire/ -- Biaosetu (Beijing) Pharmaceutical Technology Co., Ltd. (“Biaosetu”, stock code 02315.HK) and Lepucuangyi Biotechnology (Shanghai) Co., Ltd. (“Lepucuang 1”) jointly announced that they have made landmark progress by cooperating to develop three-specific T-cell connectors for intracellular targets. In just one year since the cooperation was reached, the two sides have screened the T-cell connector-WT1xCD3x4-1bb triple antibody targeting WT1/HLA-A02. Candidate antibodies for various hematomas and solid tumors
Analysis
Price Target
No Data
